Cargando…

Genome editing with the CRISPR‐Cas system: an art, ethics and global regulatory perspective

Over the last three decades, the development of new genome editing techniques, such as ODM, TALENs, ZFNs and the CRISPR‐Cas system, has led to significant progress in the field of plant and animal breeding. The CRISPR‐Cas system is the most versatile genome editing tool discovered in the history of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Debin, Hussain, Amjad, Manghwar, Hakim, Xie, Kabin, Xie, Shengsong, Zhao, Shuhong, Larkin, Robert M., Qing, Ping, Jin, Shuangxia, Ding, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336378/
https://www.ncbi.nlm.nih.gov/pubmed/32271968
http://dx.doi.org/10.1111/pbi.13383
_version_ 1783554306273705984
author Zhang, Debin
Hussain, Amjad
Manghwar, Hakim
Xie, Kabin
Xie, Shengsong
Zhao, Shuhong
Larkin, Robert M.
Qing, Ping
Jin, Shuangxia
Ding, Fang
author_facet Zhang, Debin
Hussain, Amjad
Manghwar, Hakim
Xie, Kabin
Xie, Shengsong
Zhao, Shuhong
Larkin, Robert M.
Qing, Ping
Jin, Shuangxia
Ding, Fang
author_sort Zhang, Debin
collection PubMed
description Over the last three decades, the development of new genome editing techniques, such as ODM, TALENs, ZFNs and the CRISPR‐Cas system, has led to significant progress in the field of plant and animal breeding. The CRISPR‐Cas system is the most versatile genome editing tool discovered in the history of molecular biology because it can be used to alter diverse genomes (e.g. genomes from both plants and animals) including human genomes with unprecedented ease, accuracy and high efficiency. The recent development and scope of CRISPR‐Cas system have raised new regulatory challenges around the world due to moral, ethical, safety and technical concerns associated with its applications in pre‐clinical and clinical research, biomedicine and agriculture. Here, we review the art, applications and potential risks of CRISPR‐Cas system in genome editing. We also highlight the patent and ethical issues of this technology along with regulatory frameworks established by various nations to regulate CRISPR‐Cas‐modified organisms/products.
format Online
Article
Text
id pubmed-7336378
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-73363782020-07-08 Genome editing with the CRISPR‐Cas system: an art, ethics and global regulatory perspective Zhang, Debin Hussain, Amjad Manghwar, Hakim Xie, Kabin Xie, Shengsong Zhao, Shuhong Larkin, Robert M. Qing, Ping Jin, Shuangxia Ding, Fang Plant Biotechnol J Review Over the last three decades, the development of new genome editing techniques, such as ODM, TALENs, ZFNs and the CRISPR‐Cas system, has led to significant progress in the field of plant and animal breeding. The CRISPR‐Cas system is the most versatile genome editing tool discovered in the history of molecular biology because it can be used to alter diverse genomes (e.g. genomes from both plants and animals) including human genomes with unprecedented ease, accuracy and high efficiency. The recent development and scope of CRISPR‐Cas system have raised new regulatory challenges around the world due to moral, ethical, safety and technical concerns associated with its applications in pre‐clinical and clinical research, biomedicine and agriculture. Here, we review the art, applications and potential risks of CRISPR‐Cas system in genome editing. We also highlight the patent and ethical issues of this technology along with regulatory frameworks established by various nations to regulate CRISPR‐Cas‐modified organisms/products. John Wiley and Sons Inc. 2020-04-30 2020-08 /pmc/articles/PMC7336378/ /pubmed/32271968 http://dx.doi.org/10.1111/pbi.13383 Text en © 2020 The Authors. Plant Biotechnology Journal published by Society for Experimental Biology and The Association of Applied Biologists and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Zhang, Debin
Hussain, Amjad
Manghwar, Hakim
Xie, Kabin
Xie, Shengsong
Zhao, Shuhong
Larkin, Robert M.
Qing, Ping
Jin, Shuangxia
Ding, Fang
Genome editing with the CRISPR‐Cas system: an art, ethics and global regulatory perspective
title Genome editing with the CRISPR‐Cas system: an art, ethics and global regulatory perspective
title_full Genome editing with the CRISPR‐Cas system: an art, ethics and global regulatory perspective
title_fullStr Genome editing with the CRISPR‐Cas system: an art, ethics and global regulatory perspective
title_full_unstemmed Genome editing with the CRISPR‐Cas system: an art, ethics and global regulatory perspective
title_short Genome editing with the CRISPR‐Cas system: an art, ethics and global regulatory perspective
title_sort genome editing with the crispr‐cas system: an art, ethics and global regulatory perspective
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336378/
https://www.ncbi.nlm.nih.gov/pubmed/32271968
http://dx.doi.org/10.1111/pbi.13383
work_keys_str_mv AT zhangdebin genomeeditingwiththecrisprcassystemanartethicsandglobalregulatoryperspective
AT hussainamjad genomeeditingwiththecrisprcassystemanartethicsandglobalregulatoryperspective
AT manghwarhakim genomeeditingwiththecrisprcassystemanartethicsandglobalregulatoryperspective
AT xiekabin genomeeditingwiththecrisprcassystemanartethicsandglobalregulatoryperspective
AT xieshengsong genomeeditingwiththecrisprcassystemanartethicsandglobalregulatoryperspective
AT zhaoshuhong genomeeditingwiththecrisprcassystemanartethicsandglobalregulatoryperspective
AT larkinrobertm genomeeditingwiththecrisprcassystemanartethicsandglobalregulatoryperspective
AT qingping genomeeditingwiththecrisprcassystemanartethicsandglobalregulatoryperspective
AT jinshuangxia genomeeditingwiththecrisprcassystemanartethicsandglobalregulatoryperspective
AT dingfang genomeeditingwiththecrisprcassystemanartethicsandglobalregulatoryperspective